Stopping vs. continuing JAK inhibitors for ulcerative colitis in deep remission
Part of Digestive system clinical trials.
This trial tests whether people with ulcerative colitis who are in deep remission (no symptoms and healed gut lining) can safely stop taking their JAK inhibitor (tofacitinib, upadacitinib, or filgotinib) instead of continuing the usual maintenance dose. It aims to see if stopping is as effective and safer over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 6 months
- You are 18 years or older
- You are currently taking tofacitinib, upadacitinib, or filgotinib for more than 12 months
- You have been on a stable dose of your JAK inhibitor for at least 6 months
- You have had no symptoms (like bleeding) and a healed colon lining for at least 6 months
- You have no known risks for blood clots, heart problems, or cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This trial tests if older adults with ulcerative colitis who have been in remission for a long time can safely stop taking their immune-suppressing medication (thiopurine). It may help reduce medication side effects while keeping the disease under control.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
Hear when a new Ulcerative Colitis in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.